These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 31866087

  • 1. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
    de Perrot M, Wu L, Cabanero M, Perentes JY, McKee TD, Donahoe L, Bradbury P, Kohno M, Chan ML, Murakami J, Keshavjee S, Tsao MS, Cho BCJ.
    J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
    [Abstract] [Full Text] [Related]

  • 2. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 3. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 4. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 5. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 Sep 01; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
    Fusco N, Vaira V, Righi I, Sajjadi E, Venetis K, Lopez G, Cattaneo M, Castellani M, Rosso L, Nosotti M, Clerici M, Ferrero S.
    Lung Cancer; 2020 Dec 01; 150():53-61. PubMed ID: 33065463
    [Abstract] [Full Text] [Related]

  • 7. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
    Okita R, Mimura-Kimura Y, Kawamoto N, Yamamoto N, Umeda M, Okada M, Inokawa H, Mimura Y, Murakami T, Nakata M, Okabe K.
    Cancer Immunol Immunother; 2023 Apr 01; 72(4):865-879. PubMed ID: 36115921
    [Abstract] [Full Text] [Related]

  • 8. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct 01; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 9. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D.
    Mol Biol Rep; 2019 Jun 01; 46(3):2713-2720. PubMed ID: 30840203
    [Abstract] [Full Text] [Related]

  • 10. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, Mitchell P, Watkins DN, Boutros PC, John T.
    J Thorac Oncol; 2017 May 01; 12(5):850-859. PubMed ID: 28257959
    [Abstract] [Full Text] [Related]

  • 11. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
    Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T, Torigoe T, Nishimura M.
    Cancer Immunol Immunother; 2010 Oct 01; 59(10):1543-9. PubMed ID: 20567822
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.
    Lee HS, Hamaji M, Palivela N, Jang HJ, Splawn T, Ramos D, Lee AK, Raghuram AC, Ramineni M, Amos CI, Ripley RT, Burt BM.
    Ann Thorac Surg; 2021 Nov 01; 112(5):1575-1583. PubMed ID: 33248997
    [Abstract] [Full Text] [Related]

  • 13. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC.
    J Cancer Res Clin Oncol; 2019 Apr 01; 145(4):1043-1053. PubMed ID: 30874889
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer.
    Wang Q, Lou W, Di W, Wu X.
    Int Immunopharmacol; 2017 Nov 01; 52():7-14. PubMed ID: 28846888
    [Abstract] [Full Text] [Related]

  • 15. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb 01; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N, Winkelmann R, Oppermann J, Ghanaati S, Martin D, Neumayer T, Balster S, Rödel C, Rödel F, von der Grün J, Balermpas P.
    Oral Oncol; 2020 Dec 01; 111():104931. PubMed ID: 32736208
    [Abstract] [Full Text] [Related]

  • 17. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P, Xiao Q, Zhou B, Dai Z, Kang Y.
    World Neurosurg; 2019 Sep 01; 129():e240-e254. PubMed ID: 31128313
    [Abstract] [Full Text] [Related]

  • 18. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS, Abdelwahab K, Farrag NS, Elrefaie WE, Emarah Z.
    J Egypt Natl Canc Inst; 2021 Jul 09; 33(1):16. PubMed ID: 34241710
    [Abstract] [Full Text] [Related]

  • 19. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.
    Yang H, Berezowska S, Dorn P, Zens P, Chen P, Peng RW, Marti TM, Kocher GJ, Schmid RA, Hall SRR.
    Theranostics; 2022 Jul 09; 12(1):167-185. PubMed ID: 34987640
    [Abstract] [Full Text] [Related]

  • 20. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb 09; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.